Antibody validation by combining immunohistochemistry and protein extraction from formalin-fixed paraffin-embedded tissues

Histopathology

Volumn 60, Issue 6 B, 2012, Pages

  Schuster, Claudia ^a   Malinowsky, Katharina ^b   Liebmann, Sibylle ^a   Berg, Daniela ^b   Wolff, Claudia ^b   Tran, Kai ^b   Schott, Christina ^b   Reu, Simone ^a   Neumann, Jens ^a   Faber, Claudius ^a   Höfler, Heinz ^b   Kirchner, Thomas ^a   Becker, Karl Friedrich ^b   Hlubek, Falk ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Antibody validation; Archival tissue; Biomarker; Breast cancer; Colorectal cancer; Formalin fixed paraffin embedded; Immunohistochemistry; Protein; Reverse phase protein microarrays

Indexed keywords

BETA CATENIN; BIRC3 PROTEIN; CASPASE 8; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLICE INHIBITORY PROTEIN; FORMALDEHYDE; HEAT SHOCK PROTEIN 70; PROGESTERONE RECEPTOR; PROTEIN; SNAI1 PROTEIN; TNFAIP8 PROTEIN; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; UVOMORULIN; VIM PROTEIN; ZEB1 PROTEIN;

ANTIBODY SPECIFICITY; ANTIGEN DETECTION; ARTICLE; CONTROLLED STUDY; EMBEDDING; EXTRACTION; HUMAN; HUMAN TISSUE; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; PRIORITY JOURNAL; PROTEIN LOCALIZATION; REPRODUCIBILITY; VALIDATION STUDY; WESTERN BLOTTING;

ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; FIXATIVES; FORMALDEHYDE; IMMUNOHISTOCHEMISTRY; PARAFFIN EMBEDDING; PROTEIN ARRAY ANALYSIS; REPRODUCIBILITY OF RESULTS; TISSUE FIXATION;

EID: 84860325915     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2012.04184.x     Document Type: Article

References (37)

1. Brennan DJ, O'Connor DP, Rexhepaj E, Ponten F, Gallagher WM. Antibody-based proteomics: fast-tracking molecular diagnostics in oncology. Nat. Rev. Cancer 2010; 10; 605-617.
2. Gonzalez-Angulo AM, Hennessy BTJ, Mills GB. Future of personalized medicine in oncology: a systems biology approach. J. Clin. Oncol. 2010; 28; 2777-2783.
3. Sawyers CL. The cancer biomarker problem. Nature 2008; 452; 548-552.
4. van't Veer LJ, Bernards R. Enabling personalized cancer medicine through analysis of gene-expression patterns. Nature 2008; 452; 564-570.
5. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004; 351; 2817-2826.
6. van't Veer LJ, Dai H, van de Vijver MJ et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415; 530-536.
7. Harris TJ, McCormick F. The molecular pathology of cancer. Nat. Rev. Clin. Oncol. 2010; 7; 251-265.
8. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br. J. Cancer 2007; 97; 453-457.
9. Anagnostou VK, Welsh AW, Giltnane JM et al. Analytic variability in immunohistochemistry biomarker studies. Cancer Epidemiol. Biomarkers Prev. 2010; 19; 982-991.
10. Dempke WC, Suto T, Reck M. Targeted therapies for non-small cell lung cancer. Lung Cancer 2010; 67; 257-274.
11. Eberhard DA, Giaccone G, Johnson BE. Biomarkers of response to epidermal growth factor receptor inhibitors in Non-Small-Cell Lung Cancer Working Group: standardization for use in the clinical trial setting. J. Clin. Oncol. 2008; 26; 983-994.
12. Malinowsky K, Wolff C, Ergin B, Berg D, Becker K. Deciphering signaling pathways in clinical tissues for personalized medicine using protein microarrays. J. Cell. Physiol. 2010; 225; 364-370.
13. Wulfkuhle J, Edmiston K, Liotta L, Petricoin ER. Technology insight: pharmacoproteomics for cancer--promises of patient-tailored medicine using protein microarrays. Nat. Clin. Pract. Oncol. 2006; 3; 256-268.
14. Jositsch G, Papadakis T, Haberberger RV, Wolff M, Wess J, Kummer W. Suitability of muscarinic acetylcholine receptor antibodies for immunohistochemistry evaluated on tissue sections of receptor gene-deficient mice. Naun. Schmiedebergs Arch. Pharmacol. 2009; 379; 389-395.
15. Michel M, Wieland T, Tsujimoto G. How reliable are G-protein-coupled receptor antibodies? Naun. Schmiedebergs Arch. Pharmacol. 2009; 379; 385-388.
16. Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J, Bardelli A. Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl Cancer Inst. 2009; 101; 1308-1324.
17. Goldstein NSMD, Hewitt SMMDP, Taylor CRMDD, Yaziji HMD, Hicks DGMD, Members of Ad-Hoc Committee on Immunohistochemistry S. Recommendations for improved standardization of immunohistochemistry. Appl. Immunohistochem. Mol. Morphol. 2007; 15; 124-133.
18. Hsi ED. A practical approach for evaluating new antibodies in the clinical immunohistochemistry laboratory. Arch. Pathol. Lab. Med. 2001; 125; 289-294.
19. McShane L, Altman D, Sauerbrei W, Taube S, Gion M, Clark G. REporting recommendations for tumor MARKer prognostic studies (REMARK). Breast Cancer Res. Treat. 2006; 100; 229-235.
20. Saper CB, Sawchenko PE. Magic peptides, magic antibodies: guidelines for appropriate controls for immunohistochemistry. J. Comp. Neurol. 2003; 465; 161-163.
21. Bordeaux J, Welsh A, Agarwal S et al. Antibody validation. BioTechniques 2010; 48; 197-209.
22. Mathieu A, Weynand B, Verbeken E et al. Comparison of four antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in non-small cell lung cancer. Lung Cancer 2010; 69; 46-50.
23. Major SM, Nishizuka S, Morita D et al. AbMiner: a bioinformatic resource on available monoclonal antibodies and corresponding gene identifiers for genomic, proteomic, and immunologic studies. BMC Bioinform. 2006; 7; 192.
24. Skliris G, Rowan B, Al-Dhaheri M et al. Immunohistochemical validation of multiple phospho-specific epitopes for estrogen receptor α (ERα) in tissue microarrays of ERα positive human breast carcinomas. Breast Cancer Res. Treat. 2009; 118; 443-453.
25. Becker KF, Kremmer E, Eulitz M et al. Analysis of E-cadherin in diffuse-type gastric cancer using a mutation-specific monoclonal antibody. Am. J. Pathol. 1999; 155; 1803-1809.
26. Becker KF, Schott C, Hipp S et al. Quantitative protein analysis from formalin-fixed tissues: implications for translational clinical research and nanoscale molecular diagnosis. J. Pathol. 2007; 211; 370-378.
27. Rockberg J, Lofblom J, Hjelm B, Uhlen M, Stahl S. Epitope mapping of antibodies using bacterial surface display. Nat. Meth. 2008; 5; 1039-1045.
28. Pradidarcheep W, Labruyere WT, Dabhoiwala NF, Lamers WH. Lack of specificity of commercially available antisera: better specifications needed. J. Histochem. Cytochem. 2008; 56; 1099-1111.
29. Hamdani N, van der Velden J. Lack of specificity of antibodies directed against human beta-adrenergic receptors. Naun. Schmiedebergs Arch. Pharmacol. 2009; 379; 403-407.
30. Paavilainen L, Edvinsson A, Asplund A et al. The impact of tissue fixatives on morphology and antibody-based protein profiling in tissues and cells. J. Histochem. Cytochem. 2010; 58; 237-246.
31. Stadler C, Skogs M, Brismar H, Uhlen M, Lundberg E. A single fixation protocol for proteome-wide immunofluorescence localization studies. J. Proteomics 2010; 73; 1067-1078.
32. Willingham MC. Conditional epitopes: is your antibody always specific? J. Histochem. Cytochem. 1999; 47; 1233-1236.
33. Josephsen K, Smith CE, Nanci A. Selective but nonspecific immunolabeling of enamel protein-associated compartments by a monoclonal antibody against vimentin. J. Histochem. Cytochem. 1999; 47; 1237-1246.
34. Franklin M, Carey F, Vajdos D, Leahy A, de Vos A, D'Sliwkowski M. Insights into ErbB signaling for the structure of the ErbB2-pertuzumab complex. Cancer Cell 2004; 5; 317-328.
35. Pradidarcheep W, Stallen J, Labruyere WT, Dabhoiwala NF, Michel MC, Lamers WH. Lack of specificity of commercially available antisera against muscarinergic and adrenergic receptors. Naun. Schmiedebergs Arch. Pharmacol. 2009; 379; 397-402.
36. Handschuh G, Candidus S, Luber B et al. Tumour-associated E-cadherin mutations alter cellular morphology, decrease cellular adhesion and increase cellular motility. Oncogene 1999; 18( 30 ); 4301-4312.
37. Berg D, Hipp S, Malinowsky K, Böllner C, Becker KF. Molecular profiling of signalling pathways in formalin-fixed and paraffin-embedded cancer tissues. Eur. J. Cancer 2010; 46( 1 ); 47-55.